Back HCV Treatment

Simeprevir Label Adds Interactions with Transplant Rejection Drugs

The U.S. Food and Drug Administration recently approved revisions to the product label information for Janssen's new hepatitis C protease inhibitor simeprevir (Olysio), noting drug interactions with cyclosporine and tacrolimus, which are used to prevent organ rejection after a transplant.

alt

Read more: